Funding and Investments

Jan 01, 2013
BioPharm International
A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.
Oct 01, 2012
BioPharm International
A handful of therapeutics have performed extremely well in 2012, but as a whole, life-sciences are still down from 2010.
Jul 01, 2012
BioPharm International
Collaborative R&D models coincide with new ways to fund translational research.
Apr 01, 2012
BioPharm International
Better news about the global economy buoys life-sciences funding.
Feb 01, 2012
BioPharm International
Industry announces plans for year ahead at annual JPMorgan Global Healthcare Conference.
Jan 01, 2012
BioPharm International
Greater emphasis on focus and efficiency for companies as market demands value in 2012.
Oct 01, 2011
BioPharm International
Volatile Markets Take a Toll on Life-Sciences Initial Public Offerings
Sep 20, 2011
BioPharm International
By BioPharm International Editors
The UK?s Technology Strategy Board has partnered with the Engineering and Physical Sciences Research Council (EPSRC) to invest as mush as £9 million ($14.2 million) in grant funding with the aim of bringing proof-of-concept ideas to pilot technology demonstration for healthcare.
Jul 01, 2011
BioPharm International
Strong pipelines, approvals, and deals drive up market cap.
May 10, 2011
BioPharm International
On Apr. 29, 2011, a federal appeals court has lifted a ban on federal funding for embryonic stem cell (ESC) research. The move was celebrated by researchers hoping to use such cells for research, but it is likely that the decision will be appealed. Embryonic stem cells are pluripotent cells derived from embryonic tissue in a process that usually results in the destruction of the embryo. The ban on funding did not apply to stem cells derived from adult tissue.
native1_300x100
lorem ipsum